Human retinal pigment epithelial lysis of extracellular matrix: Functional urokinase plasminogen activator receptor, collagenase, and elastase

Transactions of the American Ophthalmological Society

Volumn 100, Issue , 2002, Pages 273-299

  Elner, Susan G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 INTEGRIN; COLLAGEN; COLLAGENASE; ELASTASE; ELASTIN; INTERLEUKIN 1BETA; PHENANTHROLINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRITIUM; UROKINASE RECEPTOR; CELL SURFACE RECEPTOR; INTERLEUKIN 1; PANCREATIC ELASTASE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS;

CELL CULTURE; CELL MIGRATION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ISOTOPE LABELING; PIGMENT EPITHELIUM; POLARIZATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RETINA DISEASE; ARTICLE; BIOSYNTHESIS; CELL MOTION; CYTOLOGY; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; UPREGULATION;

CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; COLLAGENASES; ELASTIN; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INTERLEUKIN-1; PANCREATIC ELASTASE; PIGMENT EPITHELIUM OF EYE; PLASMINOGEN ACTIVATORS; RECEPTORS, CELL SURFACE; UP-REGULATION;

EID: 0036987654     PISSN: 00659533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (204)

1. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988;32:375-413.
2. Green WR, Enger C. Age related macular degeneration histopathological studies. Ophthalmology 1993;100:1519-1535.
3. Hogan MJ. Role of the retinal pigment epithelium in macular disease. Trans Am Acad Ophthalmol Otolaryngol 1972;76:64-80.
4. Feeney-Burns L, Ellersieck M. Age-related changes in the ultrastructure of Bruch's membrane. Am J Opthalmol 1985;100:686-697.
5. Green WR. The retina. In: Spencer WH, ed. Ophthalmic Pathology. An Atlas and Textbook. Philadelphia: WB Saunders; 1996: 982-1050.
6. Green WR, Key SN III. Senile macular degeneration. A histopathologic study. Trans Am Ophthalmol Soc 1977;75:951-955.
7. Green WR. Clinicopathologic studies of treated choroidal neovascular membranes. A review and report of two cases. Retina 1991;11:328-356.
8. Lopez PF, Grossniklaus HE, Lambert HM, et al. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1991;112:647-656.
9. Saxe SJ, Grossniklaus HE, Lopez PF, et al. Ultrastructural features of surgically excised subretinal neovascular membranes in the ocular histoplasmosis syndrome. Arch Ophthalmol 1993;111:88-95.
10. Grossniklaus HE, Martinez JA, Brown VE, et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992;114:464-472.
11. Grossniklaus HE, Hutchinson AK, Capone A Jr, et al. Clinicopathologic features of surgically excised choroidal neovascular membranes. Ophthalmology 1994;101:1099-1111.
12. Grossniklaus HE, Green WR. Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization. Arch Ophthalmol 1998;116:745-749.
13. Weber BHF, Vogt G, Wolz W, et al. Sorsby's fundus dystrophy is genetically linked to chromosome 22q13-qter. Nature Genet 1994;7:158-161.
14. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-125.
15. Weber BHF, Vogt G, Pruett RC, et al. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nature Genet 1994;8:352-356.
16. Capon MRC, Marshall J, Krafft JI, et al. Sorsby's fundus dystrophy - A light and electron microscopic study. Ophthalmology 1989;96:1769-1777.
17. Fariss RN, Apte SS, Luthert PJ, et al. Accumulation of tissue inhibitor of metalloproteinases-3 in human eyes with Sorsby's fundus dystrophy or retinitis pigmentosa. Br J Ophthalmol 1998;82:1329-1334.
18. Kamei M, Hollyfield JG. TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration. Invest Ophthalmol Vis Sci 1999;40:2367-2375.
19. Bressler SB, Bressler NM, Alexander J, et al. Clinicopathologic correlation of occult choroidal neovascularization in age-related macular degeneration. Arch Ophthalmol 1992;110:827-832.
20. Gass DM. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol 1973;90:201-217.
21. Green WR, Key SN. Pathologic features of senile macular degeneration. Ophthalmology 1985;92:615-627.
22. Sarks SH. Aging and degeneration in the macular region: a clinicopathologic study. Br J Ophthalmol 1976;60:324-341.
23. Smiddy WE, Fine SL. Prognosis of patients with bilateral macular drusen. Ophthalmology 1984;91:271-284.
24. Wright JK, Cawston TE, Hazleman BL. Transforming growth factor beta stimulates the production of the tissue inhibitor of metalloproteinases (TIMP) by human synovial and skin fibroblasts. Biochim Biophys Acta 1991;1094:207-210.
25. Stetler S. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic invervention. J Clin Invest 1999;103:1237-1241.
26. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001;33:960-970.
27. Butler TA, Zhu C, Mueller RA, et al. Inhibition of ovulation in the perfused rat ovary by the synthetic collagenase inhibitor SC 44463. Biol Reprod 1991;44:1183-1188.
28. Grahan CH, Lala PK. Mechanism of control trophoblast invasion in situ. J Cell Phys 1991;148:228-234.
29. Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expresion and susceptibility of various diseases. Matrix Biol 2000;19:623-629.
30. Jackson C, Nguyen M, Arkell J, et al. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis - targetting gelatinase A activation. Inflamm Res 2001;50:183-186.
31. Zucker S, Lysik RM, Zarrabi MH, et al. Elevated plasma stromelysin levels in arthritis. J Rheumatol 1991;21:2329-2333.
32. Naito K, Takahashi M, Kushida K, et al. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metaloproteinases-1 (TIMP-1) in patients with knee osteoarthritis; comparison with generalized osteoarthritis. Rheumatology (Oxford) 1999;38:510-515.
33. Liotta L, Steeg PS, Stetler Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;327-336.
34. McCawley LJ, Matrisian LM. Tumor progression:defining the soil round the tumor seed. Curr Biol 2001;11:R25-R27.
35. McMillan WD, Pearce WH. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms. J Vasc Surg 1999;29:122-127.
36. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteinases-2, and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-372.
37. Henney AM, Wakeley PR, Davies MJ, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 1991;88:8154-8158.
38. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
39. Kleiner DE, Stetler Stevenson WG. Matrix metalloproteinases and metastasis. (Abstract) Cancer Chemo Pharmacol 1999;43(Suppl):S42-S51.
40. Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res 2000;6:4823-4830.
41. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21492.
42. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-462.
43. Murray GI, Duncan ME, O'Neil P, et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-261.
44. Ito T, Ito M, Shiozawa J, et al. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol 1999;12:669-675.
45. Walsh DA. Angiogenesis and arthritis. Rheumatology 1999;38:103-12.
46. Frisch SM, Morasaki JH. Positive and negative transcriptional elements of the human type IV collagenase gene. Mol Biol Cell 1990;10:6524-6532.
47. Olson MW, Gervasi DC, Mobashery S, et al. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase TIMP-1 and TIMP-2. J Biol Chem 1977;272:29975-29983.
48. Howard E, Bulleten E, Banda MJ. Regulation of the autoactivation of human 72kDa progelatinase by tissue inhibitor of metalloproteinase-2. J Biol Chem 1991;266:13064-13069.
49. Jackson CJ, Arkell J, Nguyen M. Rheumatoid synovial endothelial cells secrete decreased levels of tissue inhibitor of MMP (TIMP1). Ann Rheum Dis 1998;57:158-161.
50. Opdenakker G, Van den Steen PE, Dubois B, et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2002;69:851-859.
51. Fenton JW. Regulation of thrombin generation and functions. Semin Thromb Hemost 1988;14:234-239.
52. Nguyen M, Arkell J, Jackson CJ. Active and tissue inhibitor of matrix metalloproteinase-free gelatinase B accumulates within human microvascular endothelial vesicles. J Biol Chem 1998;273:5400-5404.
53. Opdenakker G, Masure S, Grillet B, et al. Cytokine-mediated regulation of human leukocyte gelatinases and role in arthritis. Lymphokine Cytokine Res 1991;10:317-324.
54. Gijbels K, Masure S, Carton H, et al. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34.
55. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1β processing. J Immunol 1998;161:3340-3346.
56. McQuibban GA, Gong J-H, Tam EM, et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 200;289:1202-1206.
57. Nagase H. Stromelysins 1 and 2. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego: Academic Press; 1998:43-84.
58. Newman KM, Ogata Y, Malon AM, et al. Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb 1994;14:1315-1320.
59. Alexander JP, Bradley JMB, Gabourel JD, et al. Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium. Invest Ophthalmol Vis Sci 1990;31:2520-2528.
60. Schonfeld CL. Metalloproteinase stromelysin. Expression in humanem retinalem pigmentepithel (RPE). Ophthalmologe 1997;94:629-633.
61. Hunt RC, Fox A, Pakalnis VA, et al. Cytokines cause cultured retinal pigment epithelial cells to secrete metalloproteinases and to contract collagen gels. Invest Ophthalmol Vis Sci 1993;34:3179-3186.
62. Vaisanen A, Kallioinen M, Von Dickhoff K, et al. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - a new prognostic marker in uveal melanoma. J Pathol 1999;188:56-62.
63. Ruiz A, Brett P, Bok D. TIMP-3 is expressed in the human retinal pigment epithelium. Biochem Biophys Res Comm 1996;226:467-474.
64. Andreasen PA, Kjoller L, Christensen L, et al. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
65. Ploug M, Ronne E, Behrendt N, et al. Cellular receptor for urokinase plaminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidyl-inositol. J Biol Chem 1991;266:1926-1933.
66. Stoppelli MP, Corti A, Soffientini A, et al. Differentiation-enhanced binding of the amino-teminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 1985;82:4939-4943.
67. Dano K, Behrendt N, Brenner N, et al. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994;8:189-203.
68. Plesner T, Ploug M, Ellis V, et al. The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 1994;83:808-815.
69. McNeill H, Jensen PJ. A high-affinity receptor for urokinase plasminogen activator on human keratinocytes: characterization and potential modulation during migration. Cell Regul 1990;1:843-852.
70. Miles LA, Levin EG, Plescia J, et al. Plasminogen receptors, urokinase receptors, and their modulation on human endothelial cells. Blood 1988;72:628-635.
71. Hollas W, Hoosein N, Chung W, et al. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb Haemost 1992;68:662-666.
72. Boyd D, Florent H, Kin P, et al. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 1988;48:3112-3116.
73. Ghosh S, Brown R, Jones JC, et al. Urinary-type plasminogen activator (uPA) expression and uPA receptor localization are regulated by alpha 3 beta 1 integrin in oral keratinocytes. J Biol Chem 2000;275:23869-23876.
74. Kessler TL, Markus G. Epidermal growth factor and 12-tetradecanoyl phorbol 13-acetate induction of urokinase in A431 cells. Semin Thromb Hemost 1991;17:217-224.
75. Mignatti P, Mazzieri R, Rifkin DB. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J Cell Biol 1991;113:1193-1201.
76. Lund LR, Romer J, Ronne E, et al. Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor beta 1 in human A549 lung carcinoma cells. EMBO J 1991;10:3399-3407.
77. Neidbala MJ, Stein M. Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells. Biomed Biochim Acta 1991;50:427-436.
78. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 1989;264:2185-2188.
79. Olson D, Pollanen J, Hoyer-Hansen G, et al. Internalization of the urokinase-plasminogen activator type-1 complex is mediated by the uroldnase receptor. J Biol Chem 1992;267:9129-9133.
80. Kircheimer JC, Christ G, Binder BR. Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme. Eur J Biochem 1989;181:103-107.
81. Odekon LE, Sato Y, Rifkin DB. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 1992;150:258-263.
82. Gyetko MR, Sitrin RG, Fuller JA, et al. Function receptor (CD87) in neutrophil chemotaxis. J Leukoc Biol 1995;58:533-538.
83. Tripathi RC, Tripathi BJ, Park JK. Localization of urokinase-type plasminogen activator in human eyes: an immunocytochemical study. Exp Eye Res 1990;51:545-552.
84. Siren V, Stephens RW, Salonen EM, et al. Retinal pigment epithelial cells secrete urokinase-type plasminogen activator and its inhibitor PAI-1. Ophthalmic Res 1992;24:203-212.
85. Campochiaro PA, Mimuro J, Sugg R, et al. Retinal pigment epithelial cells produce a latent fibrinolytic inhibitor that is antigenically and biochemically related to type 1 plasminogen activator inhibitor produced by vascular endothelial cells. Exp Eye Res 1989;49:195-203.
86. Siren V, Immonen I, Cantell K, et al. Interferons a and g inhibit plasminogen activator inhibitor-1 gene expression in human retinal pigment epithelial cells. Ophthalmic Res 1994;25:1-7.
87. Yang Z, Cohen RL, Lui GM, et al. Thrombin increases expression of urokinase receptor by activation of the thrombin receptor. Invest Ophthalmol Vis Sci 1995;36:2254-2261.
88. Siren V, Myohanen H, Vaheri A, et al. Transforming growth factor beta induces urokinase receptor expression in cultures retinal pigment epithelial cells. Ophthalmic Res 1999;31:184-191.
89. Jerdan JA, Pepose JS, Michels RG, et al. Proliferative vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology 1989;96:801-810.
90. Marino I, Hiscott P, McKechnie N, et al. Variation in epiretinal membrane components with clinical derivation of the proliferative tissue. Br J Ophthalmol 1990;74:393-399.
91. Kauffmann DJH, van Meurs JC, Mertens DAE, et al. Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthamol Vis Sci 1994;35:900-906.
92. Elner SG, Elner VM, Jaffe GJ, et al. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045-1053.
93. Limb GA, Earley AO, Green W, et al. Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy. Curr Eye Res. 1994;13:791-798.
94. Grant MB, Guay C, Marsh R. Insulin-like growth factor 1 stimulates proliferation, migration, and plasminogen activator release by human retinal pigment epithelial cells. Curr Eye Res 1990;9:323-335.
95. Reuning U, Magdolen V, Wilhelm O, et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 1998;13:893-906.
96. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive, and chemotactic highways? Immunol Today 1997;18:415-417.
97. Fibbi G, Ziche M, Morbidelli L, et al. Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res 1988;179:385-395.
98. Gudewicz PW, Bilboa N. Human urokinase-type plasminogen activator stimulates chemotaxis of human neutophils. Biochem Biophys Res Comm 1987;147:1176-1181.
99. Resnati M, Guttinger M, Valcamonica S, et al. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996;15:1572-1582.
100. Loskutoff DJ, Curriden SA, Hu G, et al. Regulation of cell adhesion by PAI-1. APMIS 1999;107:54-61.
101. Elner VM, Schaffner T, Taylor K, et al. Immunophagocytic properties of retinal pigment epithelium cells. Science 1982;211:74-76.
102. Pavilack MA, Elner SG, Feldman LE, et al. Human RPE cells express leukocyte integrins and intercellular adhesion molecules. (Abstract) Invest Ophthalmol Vis Sci 1990;31(Suppl):372. Abstract 1828.
103. Xue W, Kindzelskii AL, Todd III RF, et al. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol 1994;152:4630-4640.
104. Arribas J, Coodly L, Vollmer P, et al. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 1996;271:11376-11382.
105. Lijnen HR. Elements of the fibrinolytic system. Ann NY Acad Sci 2001;936:226-236.
106. Koolwijk P, Sidenius N, Peters E, et al. Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12; implication for angiogenesis in fibrin matrices. Blood 2001;97:3123-3131.
107. Okamoto I, Kawano Y, Tsuiki H, et al. CD44 cleavage induced by a membrane associated metalloprotease plays a critical role in tumor cell migration. Oncogene 1999;18:1435-1446.
108. Preece G, Murphy G, Ager A. Metalloproteinase-mediated regulation of L-selectin levels on leucocytes. J Biol Chem 1996;271:11645-11640.
109. Elner SG, Strieter RM, Elner VM, et al. Monocyte chemotactic protein gene expression by cytokine-treated human retinal pigment epithelial cells. Lab Invest 1991;64:819-825.
110. Campochiaro PA, Jerdon JA, Glaser BM. The extracellular matrix of human retinal pigment epithelial cells in vivo and its synthesis in vitro. Invest Ophthalmol Vis Sci 1986;27:1615-1621.
111. 2-integrins, and src-kinases within a single receptor complex of human monocytes. J Exp Med 1995;181:1381-1390.
112. Min HY, Semnani R, Mizukami IF, et al. cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator. J Immunol 1992;148:3636-3642.
113. Todd RF, Nadler LM, Schlossman SF. Antigens on human monocytes identified by monoclonal antibodies. J Immunol 1981;126:1435-1442.
114. Todd RF, Roach JA, Arnaout MA. The modulated expression of Mo5, a human myelomonocyte plasma membrane antigen. Blood 1985;65:964-973.
115. Dana N, Styrt B, Griffin JD, et al. Two functional domains in the phagocyte membrane glycoprotein Mol identified with monoclonal antibodies. J Immunol 1986;137:3259-3263.
116. Petty HR, Francis JW, Todd RF, et al. Neutrophil C3bi receptors: formation of membrane clusters during cell triggering requires intracellular granules. J Cell Physiol 1987;133:235-242.
117. Zhou MJ, Todd RF, Petty HR. Detection of transmembrane linkages between immunoglobulin or complement receptors and the neutrophil's cortical microfilaments by resonance energy transfer microscopy. J Mol Biol 1991;218:263-268.
118. Zhou MJ, Todd RF III, van de Winkel JG, et al. Cocapping of the leukoadhesion molecules complement receptor type 3 and lymphocyte function-associated antigen-1 with Fcg receptor III on human neutrophils: possible role of lectin-like interactions. J Immunol 1993;150:3030-3041.
119. Wessendorf MW, Appel NM, Elde R. Simultaneous observation of fluorescent retrogradely labeled neurons and the immunofluorescently labeled fibers apposing them using fluoro-gold and antisera labeled with the blue fluorochrome7-amino-4-methylcoumarin-3-acetic acid (AMCA). Neurosci Lett 1987;82:121-126.
120. Francis JW, Todd RF, Boxer LA, et al. Histamine inhibits cell-spreading and C3bi receptor clustering and diminishes hydrogen peroxide production by adherent human neutrophils. J Cell Physiol 1991;147:128-137.
121. Uster PS, Pagano RE. Resonance energy transfer microscopy: observations of membrane-bound fluorescent probes in model membranes and in living cells. J Cell Biol 1986;103:1221-1234.
122. Zhou M-J, Poo H, Todd RF, et al. Surface-bound immune complexes trigger transmembrane proximity between complement receptor type 3 and the neutrophil's cortical microfilaments. J Immunol 1992;148:3550-3553.
123. Maher RJ, Cao D, Boxer LA, et al. Simultaneous calcium-dependent delivery of neutrophil lactoferrin and reactive oxygen metabolites to erythrocyte targets: evidence supporting granule-dependent triggering of superoxide release. J Cell Physiol 1993;156:226-234.
124. Kindzelskii AL, Zhou MJ, Haugland RP, et al. Oscillatory pericellular proteolysis and oxidant deposition during neutrophil locomotion. Biophys J 1998;74:90-97.
125. Garbett EA, Reed MWR, Brown NJ. Proteolysis in human breast and colorectal cancer. Br J Cancer 1999;81:287-293.
126. Kindzelskii AL, Yang Z, Nabel GJ, et al. Ebola virus secretory glycoprotein (sGP) disrupts FcgRIIIb to CR3 proximity on neutrophils. J Immunol 2000;165:953-958.
127. Li W, Yanoff M, Li Y, et al. Artificial senescence of bovine retinal pigment epithelial cells induced by near-ultraviolet in vitro. Mech Age Devel 1999;110:137-155.
128. Hed J. The extinction of fluorescence by crystal violet and its use to differentiate between attached and ingested microorganisms in phagocytosis. FEMS Microbiol Lett 1997;1:357-361.
129. LaBarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 1980;102:344-352.
130. Hu CL, Crombie G, Franzblau C. A new assay for collagenolytic activity. Anal Biochem 1978;88:638-643.
131. Banda MJ, Werb Z. Mouse macrophage elastase: purification and characterization as a metalloproteinase. Biochem J 1981;1983:589-605.
132. Elner VM, Nielsen JC, Elner SG, et al. Immunophenotypic modulation of cultured human retinal pigment epithelial cells by gamma interferon and phytohemagglutinin-stimulated human T-lymphocytes (Abstract). Invest Ophthabnol Vis Sci 1989;30(Suppl):233.
133. Horino K, Kindezelskii AL, Elner VM, et al. Tumor cell invasion model 3-dimensional matrices: demonstration of migratory pathways, collagen disruption, and intercellular cooperation. FASEB J 2001;15:932-939.
134. Esmaeli B, Elner VM, Elner SG, et al. Immunohistochemical detection of urokinase plasminogen activator receptor/Mo3 on human RPE cells (Abstract). Invest Ophthalmol Vis Sci 1994;35(Suppl):1759. Abstract 2334.
135. Vrauka JA, Johnson E, Zhu Xianghong, et al. Discrete expression and distribution pattern of TIMP-3 in the human retina and choroid. Curr Eye Res 1997;15:102-110.
136. Lijnen HR, Arza B, Van Hoef B, et al. Inactivation of plasminogen activator inhibitor-1 by specific proteolysis with stromelysin-1 (MMP-3). J Biol Chem 2000;275:37645-37650.
137. Rizzolo LJ. Basement membrane stimulates the polarized distribution of integrins but not the Na,K-ATPase in the retinal pigment epithelium. Cell Regul 1991;2:939-949.
138. Simon DI, Wei Y, Zhang L, et al. Identification of urokinase receptor-integrin interaction site. Promiscous regulator of integrin function. J Biol Chem 2000;275:10228-10234.
139. Ross GD. Regulation of the adhesion versus cytotoxic functions of the Mac-1/CR3/alphaM beta2-integrin glycoprotein. Crit Rev Immun 2000;20:197-222.
140. May AE, Neumann FJ, Schomig A, et al. VLA-4 (alpha(4)beta(1)) engagement defines a novel activation pathway for beta(2) integrin-dependent leukocyte adhesion involving the urokinase receptor. Blood 2000;96:506-513.
141. Estreicher A, Muhlhauser J, Carpentier JL, et al. The receptor for urokinase-type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990;111:783-792.
142. Chu PG, Grunwald BG. Fnnctional inhibition of retinal pigment epithelial cell-substrate adhesion with a monoclonal antibody against the beta I subunit of integrin. Invest Ophthalmol Vis Sci 1991;32:1763-1769.
143. Anderson DH, Guerin CJ, Matsumoto B, et al. Identification and localization of a beta-1 receptor from the integrin family in mammalian retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1990;31:81-93.
144. Lin W-L. Immunogold localization of extracellular matrix molecules in Bruch's membrane of the rat. Curr Eye Res 1989;8:1171-1178.
145. Moscatelli D, Jaffe E, Rifkin DB. Tetradecanoyl phorbol acetate stimulates latent collagenase production by cultured human endothelial cells. Cell 1980;20:343-351.
146. Kalebic T, Garbisa S, Glaser B, et al. Basement membrane collagen: degradation by migrating endothelial cells. Science 1983;221:281-283.
147. Li W, Yanoff M, Li Y et al. Artificial senescence of bovine retinal pigment epithelial cels induced by near-ultraviolet in vitro. Mech Age Devel 1999;110:137-55.
148. Spencer WH. Macular diseases: pathogenesis: light microscopy. Traus Am Acad Ophthamol Otolaryngol 1965;69:662-667.
149. Hogan MJ, Alvarado JA. Studies on the human macula, IV: aging changes in Bruch's membrane. Arch Ophthalmol 1967;77:410-420.
150. Garron LK. The ultrastructure of the retinal pigment epithelium, with observations on the choriocapillaris and Bruch's membrane. Trans Aro Ophthalmol Soc 1963;61:545.
151. Green WR, Key SN. Senile macular degeneration: a histopathologic study. Trans Am Ophthalmol Soc 1977;75:180-254.
152. Green WR. Clinicopathologic studies of senile macular degeneration. In: Nicholson DH, ed. Ocular Pathology Update. New York: Masson Publishing Co; 1980:118.
153. Ishibashi T, Patterson R, Ohmishi Y, et al. Formation of drusen in the human eye. Am J Ophthalmol 1986;101:342-343.
154. Dhaliwal BS, Steinbrecher UP. Scavenger receptors and oxidized low density lipoproteins. Clin Chim Acta 1999;286:191-205.
155. Eeckhout Y, Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem J 1977;166:21-31.
156. Dingle JT. The secretion of enzymes into the pericellular environment. Philosoph Trans R Soc London Series B: Biol Sci 1975;271:315-332.
157. Davies P, Allison AC. The macrophage as a secretory cell in chronic inflammation. Agents Actions 1976;6:60-74.
158. Unanue ER. Secretory function of mononuclear phagocytes. Am J Pathol 1976;83:396-417.
159. Berman M, Leary R, Gage J. Collagenase from corneal cell cultures and its modulation by phagocytosis. Invest Ophthalmol Vis Sci 1979;18:588-601.
160. Harper E. Collagenases. Annu Rev Biochem 1980;49:1063-1078.
161. Salo T, Liotta LA, Tryggvason K. Purification and characterization of a murine basement membrane collagen-degrading enzyme secreted by metastatic tumor cells. J Biol Chem 1983;358:3058-3063.
162. Werb Z, Gordon S. Elastase secretion by stimulated macrophages: characterization and regulation. J Exp Med 1975;143:361-377.
163. Banda MJ, Clark EJ, Werb Z. Limited proteolysis by macrophage elastase inactivates human a-1-proteinase inhibitor. J Exp Med 1980;152:1563-1570.
164. Banda MJ, Clark EJ, Werb Z. Selective proteolysis of immunoglobulins by mouse macrophage elastase. J Exp Med 1983157:1184-1196.
165. Penfild PL, Provis JM, Billson FA. Age-related macular degeneration: ultrastructural studies of the relationship of leukocytes to angiogenesis. Graefes Arch Clin Exp Ophthalmol 1987;225:70-76.
166. Penfild PL, Killingsworth MS, Sarks SH. Senile macular degeneration: the involvement of immunocomponent cells. Graefes Arch Clin Exp Ophthalmol 1987;223:69-76.
167. Loeffler KU, Lee R. Basal linear deposit in the human macula. Graefes Arch Clin Exp Ophthalmol 1986;224:493-501.
168. Sunderkotter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leuk Biol 1994;55:410-422.
169. Polverini PJ, Corran PS, Gimbrone MA Jr, et al. Activated macrophages induce vascular proliferation. Nature 1977;269:804-806.
170. Anin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Invest Ophthalmol Vis Sci 1994;35:3178-3188.
171. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855-868.
172. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999;40:1891-1898.
173. Otani A, Takagi H, Oh H, et al. Expression of angiopoietins and Tie2 in human choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999;40:1912-1920.
174. Bian ZM, Elner SG, Streiter RM, et al. IL-4 potentiates IL-1β and TNF-α stimulated IL-8 and MCP-1 protein production in human retinal pigment epithelial cells. Curr Eye Res 1999;18:349-357.
175. Elner VM, Streiter RM, Elner SG, et al. Neutrophil chemotactic factor (IL-8) gene expression by cytokine-treated retinal pigment epithelial cells. Am J Pathol 1990;136:745-750.
176. Pepper MS, Montesano R, Mandriota SJ, et al. Angiogenesis: a paradigm for extracellular proteolysis during cell migration and morphogenesis. Enzyme Prot 1996;49:138-162.
177. Davis GE, Pintar Allen KA, Salazar R, et al. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. J Cell Sci 2001;114:917-930.
178. DeNichilo MO, Burns GF. Granulocyte-macrophage and macrophage colony-stimulating factors diffentially regulate alpha v integrin expression on cultured human macrophages. PNAS 1993;90:2517-2521.
179. Brooks PC, Stromblad S, Sanders LC, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996;85:683-685.
180. Gailit J, Welch MP, Clark RA. TGF-beta a stimulates expression of keratinocyte integrins during re-epithelialization of cutaneous wounds. J Invest Dermatol 1994;103:221-227.
181. Browm SL, Lundgren CH, Nordt T, et al. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res 28:1815-1820.
182. Marshall JF, Nesbitt SA, Helfrich MH, et al. Integrin expression in human melanoma cell lines: heterogeneity of fibronectin receptor composition and function. Int J Cancer 1991;49:9224-9231.
183. Khatib AM, Nip J, Fallavollita L, et al. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor. Int J Cancer 2001;91:300-308.
184. Kanse SM, Kost C, Wilhelm OG, et al. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996;224:344-353.
185. Montgomery AM, Reisfeld RA, Cheresh DA. Integrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994;91:8856-8860.
186. Seftor RE, Seftor EA, Gehlsen KR, et al. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992;89:1557-1561.
187. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer 1997;71:116-122.
188. Wei Y, Waltz DA, Rao N, et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-32388.
189. Montgomery AMP, De Clerck YA., Langley KE, et al. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and
190. Monsky WL, Liu CY, Aoyama A, et al. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res 1994;54:5702-5710.
191. McCawley L J, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000;4:149-156.
192. Curran S, Murray GI. Matrix metalloproteinases in tumor invasion and metastasis. J Pathol 1999;189:300-308.
193. Ellerbrock SM, Stack MS. Membrane associated matrix metalloproteinases in metastasis. Bioessays 1999;21:940-949.
194. Murphy G, Gavrilovic J. Proteolysis and cell migration: creating a path? Curr Opin Cell Biol 1999;11:614-621.
195. Dano K, Romer J, Nielsen BS, et al. Cancer invasion and tissue remodeling: cooperation of protease systems and cell types. APMIS 1999;107:120-127.
196. Reich R, Thompson EW, Iwamoto Y, et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenases IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988;48:3307-3312.
197. Hart IR, Fidler IJ. An in vitro quantitative assay for tumor cell invasion. Cancer Res 1978;38:3218-3224.
198. Poste G, Doll J, Hart IR, et al. In vitro selection of murine B 16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 1980;40:1636-1644.
199. Towle MJ, Lee A, Maduakor EC, et al. Inhibition by 4-substituted benzo [b] thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 1993;53:2553-2559.
200. Sitrin RG, Todd RF III, Albrecht E, et al. The urokinase receptor (CD87) facilities CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 1996;97:1942-1951.
201. Gyteko M, Todd III R, Wilkinson C, et al. The urokinase receptor is required for monocyte chemotaxis in vitro. J Clin Invest 1994;93:1380-1387.
202. Koshelnick Y, Ehart M, Stockinger H, et al. Mechanisms of signaling through urokinase receptor and the cellular response. Thromb Haemostasis 1999;82:305-311.
203. Sitrin R, Pan P, Harper H, et al. Urokinase receptor (CD87) aggregation triggers phosphoinositide hydrolysis and intracellular calcium mobilization in mononuclear phagocytes. J Immunol 1999;163:6193-6200.
204. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system for regulating cell migration and invasiveness. Bioessays 1993;5:105-111.